Benzinga | Jan 19, 2021 08:56AM EST

Precision BioSciences Announces FDA Accepts IND For PBCAR19B, A Stealth Cell, CD19 Allogeneic CAR T Candidate For Non-Hodgkin Lymphoma

DURHAM, N.C., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage biotechnology company dedicated to improving life with its wholly proprietary ARCUS(r) genome editingDURHAM, N.C., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage biotechnology company dedicated to improving life with its wholly proprietary ARCUS(r) genome editing platform, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for PBCAR19B, a next-generation, stealth cell, CD19 product candidate for patients with relapsed/refractory (R/R) Non-Hodgkin Lymphoma (NHL).